Table 1. Open in new tab Sample...

Sample ID	Antibody Titer, BAU/mL	Sample Description	SARS-CoV-2 variant specific NT₅₀
A	>5680	LY-CoV555 (bamlanivimab)	1280	1280	1280^b	NN	NN
B	>5680	REGN10933 (casirivimab)	1280	1280	1280^b	20	320
C	>5680	REGN10987 (imdevimab)	1280	1280	1280^b	1280	1280
D	>5680	REGN-COV-2 combination	1280	1280	1280^b	1280	1280
1	<3.0	Negative control serum	NN	NN	NN	NN	NN
2	<3.0	Negative control serum	NN	NN	NN	NN	NN
3	1927.1	mRNA-1273	40	40	80	20	20
4	1035.3	mRNA-1273	20	40	20	10	NN
5	>5680	mRNA-1273	640	320	320	20	40
6	709.0	mRNA-1273	40	20	10	NN	NN
7	4008.3	mRNA-1273	80	80	80	20	20
8	4620.0	mRNA-1273	320	80	160	10	20
9	1940.0	mRNA-1273	80	40	20	NN	10
10	4167.0	mRNA-1273	160	40	80	40	10
11	2357.0	mRNA-1273	80	40	80	20	20
12	5584.4	mRNA-1273	80	40	80	10	20
13	310.7	BNT162b2	20	NN	10	NN	NN
14	151.6	BNT162b2	NN	NN	NN	NN	NN
15	1040.1	BNT162b2	20	10	10	NN	NN
16	4465.1	BNT162b2	160	80	80	20	20
17	>5680	BNT162b2	320	40	40	20	20
18	2441.9	BNT162b2	40	40	80	20	20
19	1019.3	BNT162b2	40	80	NT	10	10
20	1811.8	BNT162b2	320	160	NT	40	20
21	2302.8	Convalescent and BNT162b2	1280	1280	NT	160	80
22	23.7	Convalescent	160	160	NT	NN	NN
23	132.9	Convalescent	40	20	NT	NN	10
24	127.8	Convalescent	40	40	NT	NN	NN
25	62.5	Convalescent	320	160	NT	NN	NN
26	412.2	Convalescent	80	160	NT	10	10
27	302.2	Convalescent	160	80	NT	10	10
28	46.3	Convalescent	40	10	NN	NN	NN
29	<3.0	Convalescent	80	40	NN	20	10
30	159.5	Convalescent	20	20	NN	NN	NN
31	134.3	Convalescent	160	160	NN	10	20
32	240.0	Convalescent	40	40	40	10	10
33	119.0	Convalescent	10	10	10	NN	NN
34	119.0	Convalescent	10	10	10	NN	NN
35	62.5	Convalescent	160	80	160	NN	NN
36	314.5	Convalescent	80	80	160	40	20
37	>5680	Convalescent	1280	1280	1280	640	640
38	1286.8	Convalescent	40	80	160	10	40
39	987.6	Convalescent	40	40	40	20	20
40	134.3	Convalescent	20	20	20	NN	10
41	132.9	Convalescent	10	10	10	NN	NN

Sample ID

Antibody Titer, BAU/mL

Sample Description

SARS-CoV-2 variant specific NT₅₀

B.1

B.1.1.7 (Alpha)

B.1.351 (Beta)

P.2 (Zeta)

>5680

LY-CoV555 (bamlanivimab)

1280

1280^b

>5680

REGN10933 (casirivimab)

1280

1280^b

320

>5680

REGN10987 (imdevimab)

1280

1280^b

1280

>5680

REGN-COV-2 combination

1280

1280^b

1280

<3.0

Negative control serum

<3.0

Negative control serum

1927.1

mRNA-1273

1035.3

mRNA-1273

>5680

mRNA-1273

640

320

709.0

mRNA-1273

4008.3

mRNA-1273

4620.0

mRNA-1273

320

160

1940.0

mRNA-1273

4167.0

mRNA-1273

160

2357.0

mRNA-1273

5584.4

mRNA-1273

310.7

BNT162b2

151.6

BNT162b2

1040.1

BNT162b2

4465.1

BNT162b2

160

>5680

BNT162b2

320

2441.9

BNT162b2

1019.3

BNT162b2

1811.8

BNT162b2

320

160

2302.8

Convalescent and BNT162b2

1280

160

23.7

Convalescent

160

132.9

Convalescent

127.8

Convalescent

62.5

Convalescent

320

160

412.2

Convalescent

160

302.2

Convalescent

160

46.3

Convalescent

<3.0

Convalescent

159.5

Convalescent

134.3

Convalescent

160

240.0

Convalescent

119.0

Convalescent

119.0

Convalescent

62.5

Convalescent

160

314.5

Convalescent

160

>5680

Convalescent

1280

640

1286.8

Convalescent

160

987.6

Convalescent

134.3

Convalescent

132.9

Convalescent

Sample ID	Antibody Titer, BAU/mL	Sample Description	SARS-CoV-2 variant specific NT₅₀
A	>5680	LY-CoV555 (bamlanivimab)	1280	1280	1280^b	NN	NN
B	>5680	REGN10933 (casirivimab)	1280	1280	1280^b	20	320
C	>5680	REGN10987 (imdevimab)	1280	1280	1280^b	1280	1280
D	>5680	REGN-COV-2 combination	1280	1280	1280^b	1280	1280
1	<3.0	Negative control serum	NN	NN	NN	NN	NN
2	<3.0	Negative control serum	NN	NN	NN	NN	NN
3	1927.1	mRNA-1273	40	40	80	20	20
4	1035.3	mRNA-1273	20	40	20	10	NN
5	>5680	mRNA-1273	640	320	320	20	40
6	709.0	mRNA-1273	40	20	10	NN	NN
7	4008.3	mRNA-1273	80	80	80	20	20
8	4620.0	mRNA-1273	320	80	160	10	20
9	1940.0	mRNA-1273	80	40	20	NN	10
10	4167.0	mRNA-1273	160	40	80	40	10
11	2357.0	mRNA-1273	80	40	80	20	20
12	5584.4	mRNA-1273	80	40	80	10	20
13	310.7	BNT162b2	20	NN	10	NN	NN
14	151.6	BNT162b2	NN	NN	NN	NN	NN
15	1040.1	BNT162b2	20	10	10	NN	NN
16	4465.1	BNT162b2	160	80	80	20	20
17	>5680	BNT162b2	320	40	40	20	20
18	2441.9	BNT162b2	40	40	80	20	20
19	1019.3	BNT162b2	40	80	NT	10	10
20	1811.8	BNT162b2	320	160	NT	40	20
21	2302.8	Convalescent and BNT162b2	1280	1280	NT	160	80
22	23.7	Convalescent	160	160	NT	NN	NN
23	132.9	Convalescent	40	20	NT	NN	10
24	127.8	Convalescent	40	40	NT	NN	NN
25	62.5	Convalescent	320	160	NT	NN	NN
26	412.2	Convalescent	80	160	NT	10	10
27	302.2	Convalescent	160	80	NT	10	10
28	46.3	Convalescent	40	10	NN	NN	NN
29	<3.0	Convalescent	80	40	NN	20	10
30	159.5	Convalescent	20	20	NN	NN	NN
31	134.3	Convalescent	160	160	NN	10	20
32	240.0	Convalescent	40	40	40	10	10
33	119.0	Convalescent	10	10	10	NN	NN
34	119.0	Convalescent	10	10	10	NN	NN
35	62.5	Convalescent	160	80	160	NN	NN
36	314.5	Convalescent	80	80	160	40	20
37	>5680	Convalescent	1280	1280	1280	640	640
38	1286.8	Convalescent	40	80	160	10	40
39	987.6	Convalescent	40	40	40	20	20
40	134.3	Convalescent	20	20	20	NN	10
41	132.9	Convalescent	10	10	10	NN	NN

Table 1.

Open in new tab

Sample Characteristics^s

Sample ID	Antibody Titer, BAU/mL	Sample Description	SARS-CoV-2 variant specific NT₅₀
			B	B.1	B.1.1.7 (Alpha)	B.1.351 (Beta)	P.2 (Zeta)
A	>5680	LY-CoV555 (bamlanivimab)	1280	1280	1280^b	NN	NN
B	>5680	REGN10933 (casirivimab)	1280	1280	1280^b	20	320
C	>5680	REGN10987 (imdevimab)	1280	1280	1280^b	1280	1280
D	>5680	REGN-COV-2 combination	1280	1280	1280^b	1280	1280
1	<3.0	Negative control serum	NN	NN	NN	NN	NN
2	<3.0	Negative control serum	NN	NN	NN	NN	NN
3	1927.1	mRNA-1273	40	40	80	20	20
4	1035.3	mRNA-1273	20	40	20	10	NN
5	>5680	mRNA-1273	640	320	320	20	40
6	709.0	mRNA-1273	40	20	10	NN	NN
7	4008.3	mRNA-1273	80	80	80	20	20
8	4620.0	mRNA-1273	320	80	160	10	20
9	1940.0	mRNA-1273	80	40	20	NN	10
10	4167.0	mRNA-1273	160	40	80	40	10
11	2357.0	mRNA-1273	80	40	80	20	20
12	5584.4	mRNA-1273	80	40	80	10	20
13	310.7	BNT162b2	20	NN	10	NN	NN
14	151.6	BNT162b2	NN	NN	NN	NN	NN
15	1040.1	BNT162b2	20	10	10	NN	NN
16	4465.1	BNT162b2	160	80	80	20	20
17	>5680	BNT162b2	320	40	40	20	20
18	2441.9	BNT162b2	40	40	80	20	20
19	1019.3	BNT162b2	40	80	NT	10	10
20	1811.8	BNT162b2	320	160	NT	40	20
21	2302.8	Convalescent and BNT162b2	1280	1280	NT	160	80
22	23.7	Convalescent	160	160	NT	NN	NN
23	132.9	Convalescent	40	20	NT	NN	10
24	127.8	Convalescent	40	40	NT	NN	NN
25	62.5	Convalescent	320	160	NT	NN	NN
26	412.2	Convalescent	80	160	NT	10	10
27	302.2	Convalescent	160	80	NT	10	10
28	46.3	Convalescent	40	10	NN	NN	NN
29	<3.0	Convalescent	80	40	NN	20	10
30	159.5	Convalescent	20	20	NN	NN	NN
31	134.3	Convalescent	160	160	NN	10	20
32	240.0	Convalescent	40	40	40	10	10
33	119.0	Convalescent	10	10	10	NN	NN
34	119.0	Convalescent	10	10	10	NN	NN
35	62.5	Convalescent	160	80	160	NN	NN
36	314.5	Convalescent	80	80	160	40	20
37	>5680	Convalescent	1280	1280	1280	640	640
38	1286.8	Convalescent	40	80	160	10	40
39	987.6	Convalescent	40	40	40	20	20
40	134.3	Convalescent	20	20	20	NN	10
41	132.9	Convalescent	10	10	10	NN	NN

Sample ID	Antibody Titer, BAU/mL	Sample Description	SARS-CoV-2 variant specific NT₅₀
			B	B.1	B.1.1.7 (Alpha)	B.1.351 (Beta)	P.2 (Zeta)
A	>5680	LY-CoV555 (bamlanivimab)	1280	1280	1280^b	NN	NN
B	>5680	REGN10933 (casirivimab)	1280	1280	1280^b	20	320
C	>5680	REGN10987 (imdevimab)	1280	1280	1280^b	1280	1280
D	>5680	REGN-COV-2 combination	1280	1280	1280^b	1280	1280
1	<3.0	Negative control serum	NN	NN	NN	NN	NN
2	<3.0	Negative control serum	NN	NN	NN	NN	NN
3	1927.1	mRNA-1273	40	40	80	20	20
4	1035.3	mRNA-1273	20	40	20	10	NN
5	>5680	mRNA-1273	640	320	320	20	40
6	709.0	mRNA-1273	40	20	10	NN	NN
7	4008.3	mRNA-1273	80	80	80	20	20
8	4620.0	mRNA-1273	320	80	160	10	20
9	1940.0	mRNA-1273	80	40	20	NN	10
10	4167.0	mRNA-1273	160	40	80	40	10
11	2357.0	mRNA-1273	80	40	80	20	20
12	5584.4	mRNA-1273	80	40	80	10	20
13	310.7	BNT162b2	20	NN	10	NN	NN
14	151.6	BNT162b2	NN	NN	NN	NN	NN
15	1040.1	BNT162b2	20	10	10	NN	NN
16	4465.1	BNT162b2	160	80	80	20	20
17	>5680	BNT162b2	320	40	40	20	20
18	2441.9	BNT162b2	40	40	80	20	20
19	1019.3	BNT162b2	40	80	NT	10	10
20	1811.8	BNT162b2	320	160	NT	40	20
21	2302.8	Convalescent and BNT162b2	1280	1280	NT	160	80
22	23.7	Convalescent	160	160	NT	NN	NN
23	132.9	Convalescent	40	20	NT	NN	10
24	127.8	Convalescent	40	40	NT	NN	NN
25	62.5	Convalescent	320	160	NT	NN	NN
26	412.2	Convalescent	80	160	NT	10	10
27	302.2	Convalescent	160	80	NT	10	10
28	46.3	Convalescent	40	10	NN	NN	NN
29	<3.0	Convalescent	80	40	NN	20	10
30	159.5	Convalescent	20	20	NN	NN	NN
31	134.3	Convalescent	160	160	NN	10	20
32	240.0	Convalescent	40	40	40	10	10
33	119.0	Convalescent	10	10	10	NN	NN
34	119.0	Convalescent	10	10	10	NN	NN
35	62.5	Convalescent	160	80	160	NN	NN
36	314.5	Convalescent	80	80	160	40	20
37	>5680	Convalescent	1280	1280	1280	640	640
38	1286.8	Convalescent	40	80	160	10	40
39	987.6	Convalescent	40	40	40	20	20
40	134.3	Convalescent	20	20	20	NN	10
41	132.9	Convalescent	10	10	10	NN	NN

Abbreviations: BAU, binding antibody units; ID, identifier; mRNA, messenger RNA; NC, negative control serum samples; NN, no neutralization; NT, not tested; NT₅₀, microneutralization titer resulting in 50% neutralization of the indicated isolate.

^sSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody concentrations were tested with the SARS-CoV-2 IgG II Quant assay (Abbott Diagnostics), using the automated Alinity i device. The quantitative assay detects neutralizing antibodies against the receptor-binding domain of the S1 subunit of the SARS-CoV-2 spike protein (analytical measurement range, 2.98–5680 BAU/mL). Values represent means from 2 replicates.

GenBank accession numbers for the strains are as follows: B (FFM1/2020), MT358638; B1 (FFM7/2020), MT358643; B.1.351 (FFM-ZAF1/2021), MW822592; P.2 (FFM-BRA1/2021), MW822593; and B.1.1.7 (FFM-UK7931/2021), MZ427280 (except where otherwise noted for B.1.1.7).

^bGenBank accession number for B.1.1.7 (FFM-UK4604/2020), MW822594.

This Feature Is Available To Subscribers Only